WELLINGTON MANAGEMENT GROUP LLP 13D and 13G filings for Xenon Pharmaceuticals Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-02-10 11:23 am Purchase | 2025-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE | WELLINGTON MANAGEMENT GROUP LLP | 4,764,779 6.200% | 2,590,018 (+119.09%) | Filing |
| 2025-08-12 10:34 am Sale | 2025-06-30 | 13G | Xenon Pharmaceuticals Inc. XENE | WELLINGTON MANAGEMENT GROUP LLP | 2,174,761 2.800% | -1,987,893 (-47.76%) | Filing |
| 2024-02-08 10:03 am Purchase | 2023-12-29 | 13G | Xenon Pharmaceuticals Inc. XENE | WELLINGTON MANAGEMENT GROUP LLP | 4,162,654 5.560% | 4,162,654 (New Position) | Filing |